Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (127)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (3)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (443)
  2. Department of Medicine (443)
  3. Hematologic Malignancies, Division of (443)
  4. Lymphoma (443)
  5. Survivorship Research (205)
  6. Sloan Kettering Institute Postdocs (155)

More Groups

People
  1. Andrew Zelenetz (140)
  2. Ariela Noy (129)
  3. Paul Hamlin (123)
  4. Gilles Salles (109)
  5. Gunjan Shah (109)
  6. Steven Horwitz (109)

More People

Years
  1. 2025 (15)
  2. 2024 (57)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (186)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. British Journal of Haematology (14)
  6. Blood Cancer Journal (13)

More Publications

Publishers
  1. American Society of Hematology (206)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (31)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (443)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Meeting Abstract

    Deschè‚nes-Simard, X.; Bromberg, M.; Devlin, S. M.; Katz, O. B.; Ip, A.; Marcus, R.; Avigdor, A.; Ballweg, A.; Rabinovich, E.; Alhomoud, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CART cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)
    Meeting Abstract

    Palomba, M. L.; Caimi, P. F.; Mei, M.; Hernandez-Ilizaliturri, F.; Shouse, G.; Winter, A. M.; Yedinak, G.; Mou, D.; Huang, N.; Moua, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M.; Wang, M.; Arnason, J. E.; Kamdar, M.; Maloney, D. G.; Shadman, M.; Andreadis, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save